← Back

Center Laboratories

Center Laboratories, Inc., a pharmaceutical company, develops, manufactures, and sells pharmaceuticals in Taiwan and internationally. The company offers general medication pharmaceuticals comprising antipyretic analgesics, bronchodilators, anti-inflammatory preparations, antihistamines, expectorants, narcotic antitussives and expectorants, gastrointestinal preparations, non-narcotic antitussives and expectorants, and other medicines. It also provides central nervous system medication consisting of treatments for cerebrovascular disease, dementia, depression, schizophrenia, epilepsy, and Parkinson's disease. Center Laboratories, Inc. was founded in 1959 and is headquartered in Taipei, Taiwan.

Price · split & dividend adjusted
News & notes moving 4123.TWO
Digital Finance & Tokenization

Strategy pushes back on new MSCI delisting threat

Strategy, the Bitcoin treasury company led by Michael Saylor, faces a fresh MSCI delisting threat after the index provider opened a consultation on the eligibility of non-operating companies for its Global Investable Market Indexes. A simulation using May 2026 data shows Strategy, Metaplanet, and Yellow Cake could be deleted from the MSCI ACWI IMI, while SharpLink, Center Laboratories, and Lydia Holding would be placed on a watchlist. MSCI's proposed framework would exclude companies that fail an initial operating-asset test and trigger at least four of five financial flags, including operating assets below 20% of total assets and negative operating cash flow. Strategy, with a free-float-adjusted market cap of $23.9 billion in the simulation, is the largest company that could be removed, and the company responded on X saying index providers should measure markets, not decide which assets companies are allowed to own. MSCI is gathering feedback through September 30 and expects to announce results by October 16.
TheStreet·12dRead more ▾